Cell-free DNA Mutation Diagnostics Market

1. Executive Summary

2. Industry Introduction Taxonomy Market Definition

3. Market Trends and Success Factors Macro-economic Factors Market Dynamics Recent Industry Developments

4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034 Historical Analysis Future Projections

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034

• 5.1. Product Type
• 5.2. Technology
• 5.3. Application
• 5.4. Diagnostic Laboratories

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product Type

• 6.1. Kits and Assays
  • 6.1.1. cfDNA Isolation Kits
  • 6.1.2. Mutation-Specific Assays
• 6.2. Instruments
  • 6.2.1. Sequencers
  • 6.2.2. PCR Machines
• 6.3. Bioinformatics Tools
  • 6.3.1. Mutation Detection Algorithms
  • 6.3.2. Cloud-Based Analytics Platforms
• 6.4. Service Models
  • 6.4.1. Diagnostic Labs
  • 6.4.2. Outsourced Analysis Services

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Technology

• 7.1. Next-Generation Sequencing (NGS)
• 7.2. Polymerase Chain Reaction (PCR)
• 7.3. Microarrays and Hybridization-Based Assays

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application

• 8.1. Oncology
  • 8.1.1. Cancer Screening
  • 8.1.2. Therapy Monitoring
  • 8.1.3. Minimal Residual Disease (MRD) Detection
  • 8.1.4. Tumor Mutational Burden (TMB)
• 8.2. Prenatal Testing
  • 8.2.1. Non-Invasive Prenatal Testing (NIPT)
  • 8.2.2. Pregnancy Complications
• 8.3. Organ Transplantation
• 8.4. Other Applications
  • 8.4.1. Infectious Disease Diagnostics
  • 8.4.2. Neurodegenerative Disease Research

9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Diagnostic Laboratories

• 9.1. Diagnostic Laboratories
  • 9.1.1. Tier 1 Global Labs
  • 9.1.2. Specialty Oncology Labs
• 9.2. Hospitals and Clinics
  • 9.2.1. Academic Medical Centers
  • 9.2.2. Community Hospitals with cfDNA as part of routine panels
• 9.3. Research Institutions
  • 9.3.1. Cancer Genome Projects
  • 9.3.2. Universities with cfDNA innovation centers
• 9.4. Biopharma
  • 9.4.1. Companion Diagnostics (CDx)
  • 9.4.2. Drug Efficacy Trials

10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

• 10.1. North America
• 10.2. Latin America
• 10.3. Western Europe
• 10.4. Eastern Europe
• 10.5. East Asia
• 10.6. South Asia & Pacific
• 10.7. MEA

11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries

12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries

13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries

14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries

15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries

16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries

17. MEA Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries

18. Sales Forecast 2024 to 2034 By Product Type, Technology, Application, and Diagnostic Laboratories for 30 Countries

19. Competition Outlook Market Structure Analysis Company Share Analysis by Key Players Competition Dashboard

20. Company Profile

• 20.1. Illumina, Inc.
• 20.2. Natera, Inc.
• 20.3. Guardant Health, Inc.
• 20.4. Freenome Holdings, Inc.
• 20.5. GRAIL, Inc.
• 20.6. Exact Sciences Corporation
• 20.7. Foundation Medicine, Inc.
• 20.8. Biocept, Inc.
• 20.9. Thermo Fisher Scientific Inc.
• 20.10. Roche Diagnostics
• 20.11. Agilent Technologies, Inc.
• 20.12. Quest Diagnostics Incorporated
• 20.13. Laboratory Corporation of America Holdings (LabCorp)
• 20.14. Myriad Genetics, Inc.
• 20.15. BillionToOne, Inc.